SURGICEL SNoW Topical Absorbable Haemostat

SURGICEL SNoW Haemostat helps you focus on the procedure, not the bleed. One layer of SURGICEL SNoW is more effective* at achieving haemostasis than 4 layers of SURGICEL Original.¹ Customisable size and shape offer versatile control over continuous oozing bleeding.²**

Features & Benefits

Proven Bactericidal

Demonstrated in vitro bactericidal activity against the most common pathogens (MRSA, MRSE, VRE, PRSP, E. coli).^3-6

Time to Hemostasis

43% faster hemostasis with increased surface area contact^7,8***. A versatile option within the SURGICEL Family of Hemostats.¹³

Conformability and Handling

Easy to manipulate, adjust, reposition and deploy relative to Surgicel™ Original and Surgicel™ Fibrillar in open and Minimally Invasive Surgery.⁹^ Retains its shape for better handling, conformability, and easier insertion through trocars. ^10,11†

Resource Use & Length of Stay

SURGICEL™ advanced brands – SURGICEL™ Fibrillar and SURGICEL™ SNoW™ are associated with lower resource use and is attributed to lower mean length of stay for inpatients.^12††,±

References

* Reduced time to successfully achieve haemostasis under controlled conditions in a porcine splenic incision model. The ORC devices were applied in addition to gauze and the application of digital pressure.

** As Per Instructions For Use.

*** Compared to SURGICEL™ Original demonstrated in animal models.

^ According to an opinion poll of clinicians.

† Compared to SURGICEL™ Original, based on a 2010 survey of 21 surgeons, with at least 17 surgeons in agreement.

†† Compared to SURGICEL ™ Original Absorbable Hemostat.

± Matched PSM created patient cohorts for SO and SAPs were created for BC (n = 758 for both groups), CV (n = 3388 for both groups), and CEA (n = 2041 for both groups) procedures. Patients that received SAPs had a 14–16% lower mean LOS for each procedure compared to SO, as well as 12–18% lower total mean cost per discharge for each procedure (p < 0.02 for all results). Mean ICU costs for SAPs were also lower, with a reduction of 20% for BC and 19% for CV compared to SO ( p < 0.01). However, for CEA, there was no statistically significant difference in ICU costs for SAPs compared to SO.

Hutchinson, R.W., George, K., Johns, D. et al. Hemostatic efficacy and tissue reaction of oxidized regenerated cellulose hemostats. Cellulose (2013) 20: 537. doi:10.1007/s10570-012-9828-8
Ethicon, 16082018, SURGICEL™ Technical Report, Aug 2018, Data on File.
Spangler D, Rothenburger S, Nguyen K, Jampani H, Weiss S, Bhende S, In Vitro Antimicrobial Activity of Oxidized Regenerated Cellulose Against Antibiotic-Resistant Microorganisms. Surgical Infections. 2003;4(3): 255-262.
Dineen P. The effect of oxidized regenerated cellulose on experimental infected splenotomies. J Surg Res 1977;23:114-116
SURGICEL™ Absorbable Hemostat. Instructions for Use, Ethicon, Inc.
Ethicon, 056876- 160721 EMEA Surgicel Technical Report, October 2013, Ethicon Biosurgery internal document. Data on file.
Ethicon, 08‐0252, Comparison of Surgical Non‐Woven and Surgicel Original in The Acute Swine Splenic Incision Hemostasis Model, Jan 2009, Data on File.
Ethicon, 06072010, Project SNoW Design Verification Memo for Design Input, Requirement, July 2010, Data on File.
Ethicon, 12072010, Biosurgery SNoW Marketing Claims Report, July 2010, Data on File.
Ethicon, 12072012, Biosurgery SNoW™ Marketing Claims Report, July 2012, Data on File.
Ethicon, 18082018, SURGICEL™ Technical Report, Aug 2018, Data on File.
Martyn D, Kocharian R, Lim S, et al. Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures. J Med Econ. 2015;18(6):474481.
Amar A, Levy M, Applications of Topical Hemostatic Agents in Neurosurgery. Contemporary Surgery. 1996 Dec;4(6): 1-3.

172397-210330 UK